Why Farbe Firma is the Top Manufacturer of Lornoxicam for Injection
- Maulik Sudani
- Jun 27
- 8 min read
Last Updated: June 27, 2026
TL;DR: Lornoxicam for Injection - a sterile, lyophilized yellow powder of lornoxicam, a potent oxicam-class non-steroidal anti-inflammatory drug (NSAID) that inhibits both COX-1 and COX-2, supplied commonly as an 8 mg vial reconstituted with 2 mL water for injection to a 4 mg/mL solution and given intravenously or intramuscularly - is the short-acting, strongly analgesic NSAID clinicians reach for to control moderate-to-severe acute and post-operative pain when an oral dose is not practical. Because the active is light-sensitive and freeze-dried to a powder that is reconstituted at the bedside, each vial must deliver an exact, sterile, particulate-free dose at the labelled strength, with the stability-indicating assay, the related-substance (degradant) profile, the controlled residual moisture, reconstitution behaviour, light protection, fill and content uniformity, low particulate and endotoxin, a validated lyophilization and sterilisation process and verified container-closure integrity all mattering to safety and shelf life. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Lornoxicam for Injection at our Gujarat, India facility and supplies it to surgical, anaesthesia, pain-management and hospital-pharmacy services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Oxicam (enolic-acid) non-steroidal anti-inflammatory drug (NSAID) - lornoxicam is a potent, short-half-life analgesic and anti-inflammatory that inhibits both COX-1 and COX-2 to block prostaglandin synthesis, and Lornoxicam for Injection (8 mg lyophilized powder reconstituted to 4 mg/mL, intravenous or intramuscular) demands an exact, reproducible parenteral dose for moderate-to-severe acute and post-operative pain.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, validated freeze-drying (lyophilization) and light-protected vial filling lines, control of the stability-indicating assay, the related-substance profile, residual moisture, reconstitution time and clarity, fill and content uniformity, particulate and endotoxin, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data plus ICH Q1B photostability data, lyophilization-cycle and reconstituted in-use stability data, stability-indicating method-validation data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile lyophilized-powder vial contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Lornoxicam for Injection Demands a Premium Manufacturer
Lornoxicam for Injection holds a valued place in operating theatres, surgical wards, emergency departments and pain-management services across every market. It is the non-steroidal anti-inflammatory drug a clinician reaches for when acute pain has to be controlled quickly and strongly but an oral dose is not practical - the immediate aftermath of surgery, the patient kept nil-by-mouth, the acute musculoskeletal flare, the episode of lumbago or sciatica, the renal colic that needs fast, dependable relief. What makes lornoxicam distinctive is its potency for its class: it is an oxicam, an enolic-acid NSAID closely related to piroxicam and tenoxicam, but with a comparatively short half-life and a balanced, powerful inhibition of both COX-1 and COX-2 that gives strong analgesia with well-controlled, predictable duration. Used on its own or as part of a multimodal, opioid-sparing regimen, it lets the anaesthetist or surgeon take the edge off significant pain without the sedation and respiratory depression of opioids. Because it is given parenterally to patients who are often recovering from surgery, the dose from each vial must be exact, sterile, particulate-free and reliably the same from unit to unit, since the prescriber depends on a precise, ready, reproducible parenteral dose.
That clinical reality places real demands on the manufacturer. Lornoxicam for Injection is not a ready-to-use solution but a freeze-dried product - typically 8 mg of lornoxicam presented as a sterile lyophilized powder in a vial, reconstituted at the point of care with about 2 mL of water for injection to give a clear yellow 4 mg/mL solution for intravenous or intramuscular use - so the assay and content uniformity must be exact and the cake must dissolve quickly and completely. Lornoxicam is a light-sensitive yellow molecule, so it is compounded, filled and packaged under light protection, usually in amber glass, and supported by ICH Q1B photostability data. As a lyophilizate it is moisture-sensitive: residual water in the cake, measured by Karl Fischer, is a critical determinant of both chemical stability and reconstitution behaviour, so the freeze-drying cycle must be validated and tightly controlled. The manufacturer must run a stability-indicating method that resolves and quantifies lornoxicam and its degradation products without interference, confirm that the reconstituted solution is clear, yellow and free of visible and sub-visible particulates, and select and validate the right sterilisation strategy - aseptic processing of the sterile-filtered bulk followed by lyophilization, since a dried cake cannot simply be terminally autoclaved. The NSAID class cautions - the risk of gastrointestinal ulceration and bleeding, of renal impairment and fluid retention, of cardiovascular thrombotic events, and of hypersensitivity and bronchospasm in susceptible patients - must be clearly carried on the label. Choosing a Lornoxicam for Injection manufacturer that treats the stability-indicating assay, related-substance control, residual-moisture and reconstitution control, photostability, content uniformity, and particulate and endotoxin control as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Lornoxicam for Injection Manufacturer Apart
A world-class manufacturer of Lornoxicam for Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of lornoxicam with related-substance control by validated HPLC, which a potent oxicam NSAID demands; a robust, validated lyophilization and aseptic-fill process carried out under light protection, which a freeze-dried, light-sensitive, moisture-sensitive active requires from compounding through to the sealed vial; and tender-ready dossier support, including photostability and reconstituted in-use stability data, for an analgesic procured through hospital-pharmacy and ministry-of-health channels. It starts with the active - pharmacopoeial-grade lornoxicam sourced from qualified, audited API makers, with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Compounding, filling and freeze-drying then have to defend the assay, the clarity, the residual moisture and the colour of a light-sensitive powder. The bulk solution is compounded in water-for-injection under light-protected conditions, sterile-filtered through a 0.22 micron membrane and filled into amber vials under ISO Class 5 conditions, then freeze-dried on a validated lyophilization cycle and stoppered under controlled, low-humidity conditions, with the sterilisation and drying parameters locked in the master batch record. Filled units are 100 % inspected for fill, cake appearance, seal and particulate defects; in-process and release testing confirm the assay of lornoxicam by validated HPLC, the related-substance (degradant) profile, residual moisture by Karl Fischer, reconstitution time and the clarity and colour of the reconstituted solution, content and fill uniformity, visible and sub-visible particulate matter, and that endotoxin is held well within limits so the reconstituted solution is safe for intravenous and intramuscular administration. Because the active is light- and moisture-sensitive, assay accuracy, related-substance control, residual-moisture control, photostability and reconstitution behaviour are confirmed together so the assay, cake and clarity stay within specification across shelf life.
Quality Systems Behind Every Lornoxicam for Injection
Every Farbe Firma Lornoxicam for Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of lornoxicam against pharmacopoeial reference standards, control of related substances by HPLC, residual moisture by Karl Fischer, reconstitution time and the clarity and colour of the reconstituted solution, content and fill uniformity, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the vial format. Certificates of analysis are issued with full traceability back to each API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated lyophilizers, sterilisation and depyrogenation equipment, validated light-protected filling lines with 100 % inspection, controlled low-humidity powder-handling areas, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because lornoxicam is a light-sensitive, moisture-sensitive oxicam NSAID presented as a lyophilized powder and the assay, related-substance profile, residual moisture and reconstitution behaviour drive both efficacy and safety, we treat the stability-indicating assay, the related-substance profile, residual moisture and photostability as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under ICH Q1A long-term and accelerated (40 degrees C / 75 % RH) conditions and under ICH Q1B photostability, with reconstituted in-use stability documented, so the assay, cake and clarity stay within specification across the labelled shelf life.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Lornoxicam for Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad analgesia, anaesthesia and peri-operative small-volume parenteral portfolio. For Lornoxicam for Injection specifically, we supply the 8 mg lyophilized-powder vial under WHO-GMP conditions, light-protected in amber glass and reconstituted at the point of care for intravenous or intramuscular use, with country-specific strengths, fill configurations, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier - including the stability-indicating-assay, related-substance, residual-moisture, photostability, reconstitution, sterilisation and container-closure data package - ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A and ICH Q1B stability and photostability packages, reconstituted in-use stability data, stability-indicating method-validation data, lyophilization-cycle, sterilisation and container-closure reports, translated package inserts and artwork - including intravenous and intramuscular administration instructions, store-below-25-degrees-C and protect-from-light storage directions, reconstitution guidance, and the gastrointestinal, renal and cardiovascular NSAID cautions - for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Lornoxicam for Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment schedule delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding, filling and lyophilization suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team - practising pharmacists and R&D scientists - can talk through API sourcing, the development of a stability-indicating assay for an oxicam NSAID, related-substance and degradant control, light-protected lyophilized-formulation design, residual-moisture and reconstitution strategy, the validated freeze-drying cycle and aseptic-fill design, content and fill uniformity, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For a potent NSAID where dose precision, degradant control and reconstitution reliability directly govern patient safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Lornoxicam for Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Lornoxicam for Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, validated water-for-injection systems, validated freeze-drying (lyophilization) and light-protected vial filling lines, controlled low-humidity powder handling, validated sterilisation, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Lornoxicam for Injection do you supply?
Our standard presentation is the 8 mg lyophilized-powder vial of lornoxicam, reconstituted at the point of care with about 2 mL water for injection to a clear yellow 4 mg/mL solution for intravenous or intramuscular use, packaged light-protected and stored below 25 degrees C. Custom strengths, fill configurations, vial formats, co-packed diluent ampoules, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Lornoxicam for Injection mainly used for?
Lornoxicam for Injection is used for the short-term control of moderate-to-severe acute pain and post-operative pain, and of acute musculoskeletal and lumbo-sciatic pain, when oral therapy is not practical. It is a potent oxicam NSAID that inhibits both COX-1 and COX-2; Farbe Firma verifies the assay, related-substance profile, residual moisture, reconstitution behaviour, content uniformity, particulate matter and endotoxin at release so each vial delivers a precise, reproducible dose. It is given by clinicians, and the gastrointestinal, renal, cardiovascular and hypersensitivity cautions of the NSAID class are carried on the label.
Can Farbe Firma support country-specific registrations for Lornoxicam for Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, reconstituted in-use stability data, stability-indicating method-validation data, lyophilization-cycle, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Lornoxicam for Injection contract manufacturing?
MOQs vary by strength, vial size, lyophilization-cycle time, label complexity and dossier requirements. For our analgesia and peri-operative small-volume parenteral presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments